However, E2 via GPR30 was shown to inhibit the PCSK9-mediated cascade that degrades LDLR, thereby preserving LDLR expressions and keeping bloodstream LDL levels and the risk of CAD/CHD low (54). Here, PCSK9 is linked to coronary artery disorder.